2nd UPDATE: Consort Medical Agrees To Buy The Medical House
24 9월 2009 - 7:07PM
Dow Jones News
Medical device company Consort Medical PLC (CSRT.LN) Thursday
said it has agreed to buy The Medical House PLC (MLH.LN) for about
GBP16.5 million, in a deal that expands its portfolio of drug
delivery technologies to include high-tech injection systems.
Consort said the Medical House's needle-free injectors will
complement its own expertise in inhaled drug delivery systems, and
it expects the deal to boost earnings in the first fiscal year
after it completes. Annual savings of GBP500,000 from combining the
companies have already been identified.
Consort will also be able to use its Bespak manufacturing
division to ramp up production of the Medical House's products,
Consort said.
Consort Chief Executive Jonathan Glenn told Dow Jones Newswires
the Medical House has struggled to ink many deals with major
companies because it doesn't have the manufacturing capability to
meet big orders, and has instead relied on subcontractors.
He said Consort's manufacturing capacity and its existing ties
with big drug makers mean that will no longer be an issue.
The Medical House's injection systems have big growth potential,
Glenn said. Pharmaceutical companies and biotechnology firms are
increasingly focusing on biologic drugs, which are typically made
from complex proteins that are too big to be administered any other
way. About 40% of drug makers' current pipelines are biologics,
said Glenn, a sharp increase from a few years ago.
The Medical House's customers include India's Dr. Reddy's
Laboratories Ltd. (RDY) and Germany's Merck KGaA (MRK.XE). It
supplies Merck's Merck Serono biotechnology unit with its Coolclick
injectors to deliver the growth hormone Saizen.
Glenn said some of Consort's customers have long requested it
make injection devices and it will now be approaching those
companies following the acquisition. He didn't name any firms
specifically, although Consort's customers include companies like
GlaxoSmithKline PLC (GSK.LN).
Consort said it will pay 27.5 pence a share in cash to acquire
the Medical House, a 93% premium to its share price prior to
announcing it received an approach Aug. 11.
Consort said its offer has so far received the backing of
shareholders representing about 35% of the company, including the
Medical House directors.
Medical House Chairman Ian Townsend said the deal provides a
more certain investment outcome for Medical House shareholders in
the uncertain economic environment. According to its admission
document, the Medical House listed on the Alternative Investment
Market in 2000 in a share sale pitched at 50 pence a share.
Brewin Dolphin analysts Sahill Shan and Chris Glasper said in a
research note the acquisition fits well with Consort's stated aim
to broaden the markets in which it operates.
At 0934 GMT, shares in Consort Medical were up 14.5 pence, or
3.7% at 412 pence, outperforming a 0.9% lower Dow Jones U.K.
Smaller Companies index.
Shares in the Medical House shares were ahead 1.25 pence, or
4.8%, at 27.25 pence, outperforming a 0.7% lower Alternative
Investment Market.
Company Web sites: www.consortmedical.com ;
www.themedicalhouse.com
-By Rachael Gormley and Jason Douglas, Dow Jones Newswires;
44-20-7842-9272; jason.douglas@dowjones.com
Medical House (LSE:MLH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medical House (LSE:MLH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
